Sort
23,748 grants matching “melanoma”
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy
$1,107,978Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
MELANOMA PROGRESSION BY TARGETING NONCLASSICAL ANDROGEN SIGNALING
$1,107,495Trustees Of The University Of Pennsylvania, The · · FY2021 · Defense Health Agency
Natural Products Discovery and Characterization Through Network Collaborations
$1,107,439Kirk Gustafson · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
An Off-the-Shelf tumor cell vaccine with HLA-matching alleles for personalized treatment of advanced metastatic prostate cancer.
$1,106,781William Valentine Williams · Briacell Therapeutics Corp · R44 · FY2025 · CA
Functional genomic analysis of neural crest development
$1,106,637William J Pavan · National Human Genome Research Institute · ZIA · FY2021 · HG
Analysis of Dominant Megacolon: Another Hirschsprung Disease Model
$1,106,637William J Pavan · National Human Genome Research Institute · ZIA · FY2021 · HG
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
$1,106,459Harold John Burstein · Dana-Farber Cancer Inst · UG1 · FY2023 · CA
Pathways that Suppress or Accelerate Premalignant Progression of Squamous Cancer
$1,105,880Stuart H. Yuspa · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Clinical Trials and Information Management Support
$1,105,279Donald Stablein · The Emmes Company, Llc · N02 · FY2010 · CA
Genetic Epidemiology
$1,104,644Alisa Goldstein · Division Of Cancer Epidemiology And Genetics · ZIA · FY2011 · CA
Rewired Signaling at the Nexus of Melanoma Metastasis and Resistance
$1,104,636Ze'ev A Ronai · Sanford Burnham Prebys Medical Discovery Institute · R35 · FY2022 · CA
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
$1,103,993Harold John Burstein · Dana-Farber Cancer Inst · UG1 · FY2019 · CA
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
$1,103,826Harold John Burstein · Dana-Farber Cancer Inst · UG1 · FY2020 · CA
Drugs Targeting Dormant Tumors as Anti-Metastatic Agents
$1,102,521Michael A Ihnat · Dormatarg, Inc. · R44 · FY2011 · CA
IMMUNOTHERAPEUTIC TARGETING OF SLC39A9 IN CDKN2A-LOW MELANOMA
$1,101,574The Wistar Institute Of Anatomy And Biology · · FY2025 · Defense Health Agency
NIRT: Active Nanostructure Enabled On-Chip Spectroscopy System for Cancer Detection
$1,100,000Wounjhang Park · University Of Colorado At Boulder · · FY2006 · ENG
Molecular regulation in reproduction
$1,099,836Frank S French · Univ Of North Carolina Chapel Hill · U54 · FY2010 · HD
Rewired Signaling at the Nexus of Melanoma Metastasis and Resistance
$1,099,568Ze'ev A Ronai · Sanford Burnham Prebys Medical Discovery Institute · R35 · FY2019 · CA
DNA Repair in Human Cancer-Prone Genetic Diseases
$1,099,456Kenneth H Kraemer · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Genetic and molecular basis for variation in human skin pigmentation
$1,099,124Michael S Marks · Children'S Hosp Of Philadelphia · R01 · FY2022 · AR
Investigation of Germ-line Genetic Variation and Susceptibility to Cancer and it
$1,095,659Stephen J Chanock · Clinical Sciences · Z01 · FY2007 · CA
DCTD Human Toxicology and Pharmacology
$1,095,585David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2014 · CA
Animal Model and Genotyping Core Support Facility
$1,093,069Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIC · FY2018 · CA
MELANOMA ACADEMY LEADERSHIP AWARD
$1,092,000The General Hospital Corporation · · FY2022 · Department of the Army
Molecular regulation in reproduction
$1,091,840Frank S French · Univ Of North Carolina Chapel Hill · U54 · FY2011 · HD